Re: Curing AIDS with tetrasilver tetroxide molecular crystal devices

To all interested parties ... the following was received in response to an email I sent to the developer of this product on
2005.02.03.

STATEMENT ON TETRASIL® AND IMUSIL®

---------------------------------------------------

Thank your for your interest in Aidance products, makers of Tetrasil® Multi-Purpose Topical Ointment, www.Tetrasil.com

The Imusil® product, for treatment of HIV and AIDS, is still under development.

It is essential that the proper clinical studies be made to guarantee the treatment's efficacy and safety. Premature use, before the proper protocols are established, could jeopardize a patient's health, the product's development, and delay its introduction to the general public.

At Aidance, we certainly take very seriously the grave and compelling conditions of individuals battling HIV and AIDS. However, in order to help the most people in the safest way, we need to proceed in a responsible fashion. To achieve this, and bring the product to market, we are seeking investors, institutions, and donors to fund the proper studies and clinical trials.

If you know any potential investors (minimum $50K) who may be interested in our efforts, please refer them to us. You will be doing a great service to the world. These potential stakeholders may reach us at aht_info@marantech.com or call at (401) 223-3000. In the future, as more information becomes available, it will be published on www.Imusil.com.

Sincerely,

Aidance Management


ADDITIONAL FAQ's ANSWERED
---------------------------------------------------
Aidance has made no claims about an injectable form. We are hoping to conduct double blind clinical trials in the near future (funding dependent). There was an offshore clinical study on a "Compassionate Care" basis, of an injectable form of the active ingredient Tetrasilver Tetroxide (TsT). Even though the data gathering protocols were not followed to Aidance's satisfaction, and results were inconclusive by U.S. standards, the results were nonetheless encouraging. Imusil® is the current product now being developed with TsT for treating internal, systemic and life-threatening conditions.

Tetrasil's current formulation is to treat topical pathogens causing unwanted skin conditions only. HIV is a systemic life threatening condition beyond the scope of the Tetrasil® topical ointment. FDA approval process has not yet been sought for Tetrasil® topical ointment or the Imusil product (still under development).

Aidance is confident in the safety of the topical usage based on the success of earlier dermal, oral, ocular, ingestion toxicity and genotoxicity studies of the active ingredient, Tetrasilver Tetroxide (TsT). The success rate of TsT against a broad spectrum of pathogens for in-vitro experiments is very high. The anecdotal evidence from users of Tetrasil® is also very convincing.

While Imusil® is not yet available, the Tetrasil® product for topical application may offer significant relief to HIV and AIDS patients contending with a variety of topical skin conditions.

Thank you.
Tweet